News & Events
-
April 6, 2023Initiation of a new Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy [Development code: K-321]
-
March 22, 2023Initiation of a Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy [Development code: K-321]
-
September 1, 2022Kowa Pharmaceutical Asia Pte. Ltd,. has launched a new website.
-
August 26, 2022Initiation of Phase 3 clinical study in the United States Indication for Fuchs endothelial corneal dystrophy [Development code: K-321]
-
August 26, 2020K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Thailand
-
July 13, 2020K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Malaysia
-
March 11, 2020K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Singapore
-
February 19, 2020Fixed Combination Eye Drop of Ripasudil Hydrochloride Hydrate, a Rho Kinase Inhibitor, and Brimonidine Tartrate Started Phase 3 Clinical Studies in Japan[Developmental code: K-232]
-
August 7, 2014University of Tokyo's RCAST, Fujitsu, and Kowa Successfully Generate a Novel Active Compound Targeting Cancer Using IT-based Drug Discovery Technology
-
December 24, 2013December 11, 2013 - Yoshihiro Miwa, President & C.E.O. of KOWA, was honored the chair engraved with the Brigham and Women’s Hospital (BWH) logo. This chair indicates the contribution toward the medical development from BWH that operates joint research facility with KOWA.
-
October 26, 2012License Agreement of SGLT2 Inhibitor "CSG452" in Japan
-
June 6, 2012A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
A regulatory approval was obtained in January 2011. -
May 9, 2012A consolidated subsidiary of Mitsubishi Tanabe Pharma，P.T. Tanabe Indonesia，started marketing Livalo (pitavastatin)，a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor)，in Indonesia on May 1，2012.
The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011. -
February 20, 2012Eli Lilly has introduced Redevant (pitavastatin), an HMG-CoA reductase inhibitor for lowering cholesterol, in Mexico this month. The launch comes after the product received approval in July 2011 from the country's Ministry of Health.
-
August 4, 2011Mexican health authority has granted marketing authorization for pitavastatin，an HMG-CoA reductase inhibitor or statin，for treatment of hyperlipidemia. Kowa’s partner，Eli Lilly will market the product as RedevantR from early 2012.
-
May 11, 2011The HMG-CoA reductase inhibitor pitavastatin calcium (Livazo 1mg, 2mg & 4mg) has been launched in Spain on May 2, 2011 as the first European market.
Spain is co-marketed by Recordati S.p.A and ESTEVE -
January 19, 2011Peretinoin (NIK-333) Study Subanalysis Gives Clue To Mechanism of Reduced Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011
-
October 20, 2010Peretinoin（NIK-333）Data, the Results of the Clinical Pharmacology Study for Liver Gene Expression Profiles in Patients after Curative Therapy of Hepatocellular Carcinoma (HCC), To Be Presented at The 61st Annual Meeting of the American Association for the Study of Liver Diseases
-
September 13, 2010Peretinoin reduces recurrence risk of hepatocellular carcinoma after curative therapy
-
August 30, 2010Peretinoin（NIK-333）Data, the Results of the Phase II/III Trial for the Suppression of Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at the International Liver Cancer Association Annual Conference
-
December 24, 2009Kowa Company, Ltd. Opens Collaborative Cardiovascular Research Center with Brigham and Women's Hospital
-
August 3, 2009FDA Approves LIVALOR for Primary Hypercholesterolemia and Combined Dyslipidemia
FDA Approves LIVALOR for Primary Hypercholesterolemia and Combined Dyslipidemia.
Montgomery, AL and Morrisville, NC August 03, 2009 - Kowa Research Institute (KRI)based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved LIVALOR (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia.